|  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        648300240[A60350081]  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/1mL(2007.11.15)(ÇöÀç¾à°¡) 
            \7 ¿ø/1mL(2001.06.23)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¹«»ö-¹ÌȲ»öÀÇ ¸¼Àº ¾×À¸·Î ³¿»õ´Â ¾ø°í ¸ÀÀº ¾²´Ù.
  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    250, 500¹Ð¸®¸®ÅÍ , 1.5¸®ÅÍ | 
   
  
  
  
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      131306CLQ  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
  
  	
   
    | ´ëÇ¥ÄÚµå | 
    8806483002409 | 
   
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    Â÷±¤±â¹Ð¿ë±â
 | 
   
  
  
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      
 - ¼Õ ¹× ÇǺÎÀÇ ¼Òµ¶(º¸°ÇÀ§»ýÁ¾»çÀÚ ¹× ¼ö¼ú ½Ã ¼ö¼úÀÚÀÇ ¼Õ ¼Òµ¶, ¼ö¼úºÎÀ§ ÇǺÎÀÇ ¼Òµ¶Àº Á¦¿Ü) 
 - ÀÇ·á¿ë±¸ÀÇ ¼Òµ¶ 
 - °¡±¸, ±â±¸ µîÀÇ ¼Òµ¶ 
 - ÇǺÎÀÇ Ã¢»óºÎÀ§ ¼Òµ¶ 
 - »êºÎÀΰú, ºñ´¢±â°ú¿¡¼ÀÇ ¿ÜÀ½, ¿Ü¼º±âÀÇ ÇǺμҵ¶ 
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      
 ±Û·çÄÜ»êŬ·Î¸£Çí½ÃµòÀ¸·Î¼ ¿ëµµ¿¡ µû¶ó ´ÙÀ½ÀÇ ³óµµ·Î Èñ¼®ÇÏ¿© »ç¿ëÇÑ´Ù. 
 ¨ç ¼Õ ¹× ÇǺÎÀÇ ¼Òµ¶(º¸°ÇÀ§»ýÁ¾»çÀÚ ¹× ¼ö¼ú ½Ã ¼ö¼úÀÚÀÇ ¼Õ ¼Òµ¶, ¼ö¼úºÎÀ§ ÇǺÎÀÇ ¼Òµ¶Àº Á¦¿Ü) : 0.1 - 0.5% ¼ö¿ë¾× 
 ¨è ÀÇ·á¿ë±¸ÀÇ ¼Òµ¶ : 0.1 - 0.5% ¼ö¿ë¾× ¶Ç´Â 0.5% ¿¡Åº¿Ã¿ë¾× 
 ¨é °¡±¸, ±â±¸ µîÀÇ ¼Òµ¶, ÇǺÎÀÇ Ã¢»óºÎÀ§ ¼Òµ¶ : 0.05% ¼ö¿ë¾× 
 ¨ê »êºÎÀΰú, ºñ´¢±â°ú¿¡¼ÀÇ ¿ÜÀ½, ¿Ü¼º±âÀÇ ÇǺμҵ¶ : 0.02% ¼ö¿ë¾× 
     
      	    
     | 
   
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
      1) Ŭ·Î¸£Çí½ÃµòÁ¦Á¦¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ 
2) ³ú, ô¼ö, ±Í(³»ÀÌ, ÁßÀÌ, ¿ÜÀÌ)(û°¢½Å°æ ¶Ç´Â ÁßÃ߽Ű濡 Á÷Á¢ »ç¿ëÇÒ °æ¿ì ³Ã», ½Å°æÀå¾Ö¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)(5%, 20% ¾×Á¦¿¡ ÇÑÇÔ) 
3) Áú, ¹æ±¤, ±¸° µîÀÇ Á¡¸·¸é(¼ïÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖÀ¸¸ç ÃʱâÁõ»óÀ¸·Î´Â ±¸¿ª, ºÒÄè°¨, ½ÄÀº¶¡, ¾îÁö·¯¿ò, ´ä´äÇÔ, È£Èí°ï¶õ, ¹ßÀû µîÀÌ ÀÖ´Ù)(4% ¾×Á¦ Á¦¿Ü) 
4) ´«(4% ¾×Á¦ Á¦¿Ü) 
     | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    1) ´Ù¸¥ ¾à¹°¿¡ °ú¹ÎÁõ ȯÀÚ 
2) õ½Ä µî ¾Ë·¹¸£±â Áúȯ ¹× ±× º´·Â ¶Ç´Â °¡Á··ÂÀÌ Àִ ȯÀÚ 
3) ºÐ¸¸ Á÷ÀüÀÇ ¿ÜÀ½ºÎ ÁÖÀ§(½Å»ý¾ÆÀÇ ´« µî¿¡ µé¾î°¡ ¾Ç¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Ù)(5%, 20% ¾×Á¦¿¡ ÇÑÇÔ) 
 | 
   
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      1) ¼ï : µå¹°°Ô ¼ïÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ°í ±¸¿ª, ºÒÄè°¨, ½ÄÀº¶¡, ¾îÁö·¯¿ò, ´ä´äÇÔ, È£Èí°ï¶õ, ¹ßÀû µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Áï½Ã »ç¿ëÀ» ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. 
2) °ú¹ÎÁõ : ¶§¶§·Î ¹ßÁø, µÎµå·¯±â µîÀÇ °ú¹ÎÁõ»ó ¹× °í³óµµ¿¡¼ Àڱذ¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù. 
3) ±¤°¨ÀÛÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    1) ¼ï ¹ßÇö¿¡ ´ëºñÇÏ¿© »ç¿ë½Ã Ŭ·Î¸£Çí½ÃµòÁ¦Á¦¿¡ ´ëÇÑ °ú¹ÎÁõÀÇ º´·Â, ¾à¹°°ú¹ÎüÁú ¿©ºÎ µîÀ» ÃæºÐÈ÷ ¹®ÁøÇØ¾ß ÇÑ´Ù. 
2) ±Û·çÄÜ»êŬ·Î¸£Çí½Ãµò Á¦Á¦·Î ÀÎÇØ ¼ïÀ» ÀÏÀ¸Å² ȯÀÚ Áß ¸î ¸í¿¡¼ Ç÷û Áß Å¬·Î¸£Çí½Ãµò¿¡ ƯÀÌÀûÀÎ IgE Ç×ü°¡ °ËÃâµÈ º¸°í°¡ ÀÖ´Ù. 
3) À¯¸® ¶Ç´Â ±Ý¼Ó Á¢ÇպκÐÀÌ ÀÖ´Â ¾È°ú¿ë ±â±â´Â ÀÌ ¾à¿¡ ÀÇÇÏ¿© ºÎ½ÄµÇ¹Ç·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù(5%, 20% ¾×Á¦¿¡ ÇÑÇÔ). 
 | 
   
  
  
  
  
  
  
   
    | ÀӺο¡ ´ëÇÑ Åõ¿© | 
    
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]       
      ÀÌ ¾àÀº ÀӺο¡ ´ëÇÑ µ¿¹°½ÇÇèÀ̳ª ÀÓ»ó½ÃÇèÀÌ ÀüÇô ½Ç½ÃµÇÁö ¾Ê¾ÒÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¶Ç´Â ¼öÀ¯ºÎ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â´Ù.
     | 
   
  
  
  
  
   
    | ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© | 
    ÀÌ ¾àÀº ÀӺο¡ ´ëÇÑ µ¿¹°½ÇÇèÀ̳ª ÀÓ»ó½ÃÇèÀÌ ÀüÇô ½Ç½ÃµÇÁö ¾Ê¾ÒÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¶Ç´Â ¼öÀ¯ºÎ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â´Ù. | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
   
    | Àû¿ë»óÀÇ ÁÖÀÇ | 
    1) ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÑ´Ù(Å©¸²Á¦¿¡ ÇÑÇÔ). 
2) ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÏ¸ç °æ±¸Åõ¿© ¹× ÁÖ»çÇÏÁö ¾Ê´Â´Ù. ½Ç¼ö·Î ¸¶½Å °æ¿ì ¿ìÀ¯, °è¶õ, Á©¶óƾ µîÀ» ÀÌ¿ëÇÏ¿© À§¼¼Ã´ µîÀ» Çϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ½Ç¼ö·Î Á¤¸ÆÁÖ»çÇÑ °æ¿ì ¿ëÇ÷¹ÝÀÀÀ» ¹æÁöÇϱâ À§ÇØ ¼öÇ÷ÇÑ´Ù(¾×Á¦¿¡ ÇÑÇÔ). 
3) ´«¿¡ Á¢Ã˽à °¢¸·¼Õ»óÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ´«¿¡ µé¾î°¡Áö ¾Êµµ·Ï ÁÖÀÇÇÏ°í ¸¸¾à µé¾î°¬À» °æ¿ì¿¡´Â Áï½Ã ±ú²ýÇÑ ¹°·Î Àß ¾Ä¾î³½´Ù. 
4) ±¤¹üÀ§ÇÑ Ã¢»ó, Ȼ󿡴 »ç¿ëÇÏÁö ¾Ê´Â´Ù. ƯÈ÷ Á¶»ê¾Æ¤ý½Å»ý¾ÆÀÇ °æ¿ì Àü½Å ºÎÀÛ¿ëÀÇ À§ÇèÀÌ Áõ°¡µÉ ¼ö ÀÖ´Ù. 
5) ±¤¹üÀ§ÇÏ°Ô ¶Ç´Â Àå±â°£ »ç¿ëÇÏ´Â °æ¿ì¿¡´Â Áõ±â¸¦ ÈíÀÔÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù. 
6) Ç÷û, ³ó µîÀÇ À¯±â¹°ÁúÀº ÀÌ ¾àÀÇ »ì±ÕÀÛ¿ëÀ» ¾àȽÃŰ¹Ç·Î ÀÌ ¶§ »ç¿ëÇÏ´Â ÀÇ·á¿ë±¸ µîÀÇ ¼Òµ¶¿¡ ÀÌ ¾àÀ» »ç¿ëÇÏ´Â °æ¿ì ÀÌ ¾àÀ¸·Î ¿ë±¸¸¦ ÃæºÐÈ÷ ¾Ä¾î³½ ÈÄ »ç¿ëÇÑ´Ù. 
7) ºñ´©·ù´Â ÀÌ ¾àÀÇ »ì±ÕÀÛ¿ëÀ» ¾àȽÃŰ¹Ç·Î ÃæºÐÈ÷ ¾Ä¾î Á¦°ÅÇÑ ÈÄ »ç¿ëÇÑ´Ù. 
8) ÀÌ ¾àÀº ¼¶À¯¤ýÇë°Ò(¸é, °ÅÁî, ¿ï, ·¹À̿ µî)¿¡ ÈíÂøµÇ¹Ç·Î ¿ë¾×¿¡ Àû¼Å¼ »ç¿ë½Ã À¯È¿³óµµ ÀÌ»óÀÌ ¾Æ´Ò °æ¿ì »õ·Î¿î ¿ë¾×À» °ø±ÞÇÑ´Ù. 
9) ½Ä¿°¼ö µî¿¡ µé¾îÀÖ´Â À½À̿¿¡ ÀÇÇÏ¿© ³¿ë¼º¿°À» »ý¼ºÇϹǷΠÈñ¼®ÇÏ´Â °æ¿ì¿¡´Â ±ú²ýÇÑ Áõ·ù¼ö¸¦ »ç¿ëÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù(¾×Á¦¿¡ ÇÑÇÔ). 
10) ÀÌ ¾àÀÌ ºÎÂøµÇ¾î ÀÖ´Â Ä«Å×ÅÍ·Î Åõ¼®ÇÏ´Â °æ¿ì Åõ¼®¾×ÀÇ ¼ººÐÀ¸·ÎºÎÅÍ ³¿ë¼º¿°À» »ý¼ºÇϹǷΠ¸ê±Õ¼ö·Î Àß ¾Ä¾î³½ ÈÄ »ç¿ëÇÑ´Ù(5%, 20% ¾×Á¦¿¡ ÇÑÇÔ). 
11) ÀÌ ¾àÀÇ ¾ËÄڿÿë¾×ÀÇ °æ¿ì ¼ö¼úºÎÀ§ ¼Òµ¶ ÈÄ Ã³Ä¡ Àü¿¡ °ÇÁ¶ÇØ¾ß ÇÑ´Ù(Àü±â¸Þ½º µî¿¡ ÀÇÇØ ¹ßÈ»ç°íÀÇ º¸°í°¡ ÀÖ´Ù)(5%, 20% ¾×Á¦¿¡ ÇÑÇÔ). 
12) »êºÎÀΰú¿ë(Áú, ¿ÜÀ½ºÎÀÇ ¼Òµ¶ µî), ºñ´¢±â°ú¿ë(¿Ü¼º±â, Á¡¸·¸éÀÇ ¼Òµ¶ µî)À¸·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù(5% ¾×Á¦, Å©¸²Á¦¿¡ ÇÑÇÔ). 
13) â»óºÎÀ§ÀÇ Åõ¿©½Ã Èñ¼®¾× Á¶Á¦ ÈÄ ¹Ýµå½Ã ¸ê±Õó¸®ÇÑ´Ù(¾×Á¦¿¡ ÇÑÇÔ). 
14) ÁÖ»ç±â, Ä«Å×ÅÍ µî°ú °°ÀÌ ½Å°æÀ̳ª Á¡¸·¸é¿¡ Á¢ÃËÇÒ °¡´É¼ºÀÌ ÀÖ´Â ±â±¸ µîÀ» ¼Òµ¶ÇÒ °æ¿ì¿¡´Â ¸ê±Õ¼ö·Î Àß ¾Ä¾î³½ ÈÄ »ç¿ëÇÑ´Ù(5%, 20% ¾×Á¦¿¡ ÇÑÇÔ). 
15) ¼ÕÀÇ ¼¼Á¤ µî¿¡ »ç¿ëÇÏ´Â Èñ¼®¾×Àº Àû¾îµµ ¸ÅÀÏ »õ·Î¿î ¿ë¾×À¸·Î ±³È¯ÇÑ´Ù(¾×Á¦¿¡ ÇÑÇÔ). 
 | 
   
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    1) ÀÌ ¾àÀÇ È°¼º°ú ¾ÈÁ¤¼ºÀ» À§ÇÑ ÀûÁ¤ pH´Â 5 - 7ÀÌ´Ù. pH°¡ 8ÀÌ»óÀ̸é ÀÌ ¾àÀº ¿°±â°¡ µÇ¾î °áÁ¤À» Çü¼ºÇÑ´Ù(¾×Á¦¿¡ ÇÑÇÔ). 
2) Èñ¼®¼ö¿ë¾×Àº ¾ÈÁ¤Çϳª °í¿Â¿¡ Àå½Ã°£ º¸°üÇÏÁö ¾Ê´Â´Ù(°í¾ÐÁõ±â¸ê±ÕÀ» ÇàÇÏ´Â °æ¿ì 115¡É 30ºÐ, 121¡É 20ºÐ, 126¡É 15ºÐÀ¸·Î ó¸®ÇÑ´Ù). »ì±ÕÇÏÁö ¾ÊÀº Èñ¼®¾×Àº ¸¸µç Áï½Ã »ç¿ëÇϸç ÀÜ¿©ºÐÀº ¹ö¸°´Ù(¾×Á¦¿¡ ÇÑÇÔ). 
3) Èñ¼®¼ö¿ë¾×Àº Á¶Á¦ Áï½Ã »ç¿ëÇØ¾ß ÇÏÁö¸¸ ºÎµæÀÌÇÏ°Ô ¼Òµ¶¿ë ¸éºÀ µî¿¡ Àå½Ã°£ »ç¿ëÇÏ´Â °æ¿ì ¹Ì»ý¹°ÀÇ ¿À¿°À» ¹æÁöÇϱâ À§ÇØ Èñ¼®¼ö¿ë¾×¿¡ ¾ËÄÚ¿Ã µîÀ» Ãß°¡ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù(¿¡Åº¿ÃÀÇ °æ¿ì 7% ÀÌ»ó, À̼ÒÇÁ·ÎÇʾËÄÚ¿ÃÀÇ °æ¿ì 4% ÀÌ»óÀÌ µÇµµ·Ï Ãß°¡ÇÑ´Ù)(¾×Á¦¿¡ ÇÑÇÔ). 
4) ±â±¸·ùÀÇ º¸Á¸¿¡ »ç¿ëÇÏ´Â °æ¿ì ºÐÇØ¸¦ ¹æÁöÇϱâ À§ÇØ °í³óµµÀÇ Èñ¼®¾×(´ëü·Î 0.3% ÀÌ»ó)À» »ç¿ëÇÏ°í ¹Ì»ý¹°ÀÇ ¿À¿°À» ¹æÁöÇϱâ À§Çؼ´Â Èñ¼®¼ö¿ë¾×¿¡ ¾ËÄÚ¿ÃÀ» Ãß°¡ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷Çϸç(¾ËÄÚ¿ÃÀÇ Ãß°¡·®Àº 3)°ú °°´Ù) ¸ÅÁÖ »õ·Î¿î ¿ë¾×À¸·Î ±³È¯ÇÑ´Ù(5%, 20% ¾×Á¦¿¡ ÇÑÇÔ).
 | 
   
  	
  
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
  
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Bµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
  
  
  
  
  
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      ¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Chlorhexidine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Chlorhexidine's antimicrobial effects are associated with the attractions between chlorhexidine (cation) and negatively charged bacterial cells. After chlorhexidine is absorpted onto the organism's cell wall, it disrupts the integrity of the cell membrane and causes the leakage of intracellular components of the organisms. 
     | 
   
  
   
    | Pharmacology | 
     
       Chlorhexidine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Chlorhexidine, a topical antimicrobial agent, is bactericidal. Because of its positive charge, the chlorhexidine molecule reacts with the microbial cell surface to destroy the integrity of the cell membrane. This novel mechanism of action makes it highly unlikely for the development of bacterial resistance. 
     | 
   
  
   
    | Metabolism | 
    
       Chlorhexidine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available 
     | 
   
  
   
    | Protein Binding | 
    
       Chlorhexidine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 87% 
     | 
   
  
   
    | Half-life | 
    
       Chlorhexidine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available 
     | 
   
  
   
    | Absorption | 
    
       Chlorhexidine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorption of chlorhexidine from the gastrointestinal tract is very poor. Additionally, an in vivo study in 18 adult patients found no detectable plasma or urine chlorhexidine concentrations following insertion of four periodontal implants under clinical conditions. 
     | 
   
  
   
    | Toxicity | 
    
       Chlorhexidine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50= 2g/kg (human, oral); LD50= 3 g/kg (rat, oral); LD50= 2.5 g/kg (mice, oral); LD50= 21 mg/kg (male rat, IV); LD50= 23 mg/kg (female rat, IV); LD50= 25 mg/kg (male mice, IV); LD50= 24 mg/kg (female mice, IV); LD50= 1g/kg (rat, subcutaneous); LD50= 637 mg/kg (male mice, subcutaneous); LD50= 632 mg/kg (female mice, subcutaneous) 
     | 
   
  
   
    | Drug Interactions | 
    
       Chlorhexidine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Description | 
    
       Chlorhexidine¿¡ ´ëÇÑ Description Á¤º¸ A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque. [PubChem] 
     | 
   
  
   
    | Drug Category | 
    
       Chlorhexidine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsAnti-Infective Agents, LocalAnti-InfectivesDisinfectantsMouthwashes 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Chlorhexidine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(NC1=CC=C(Cl)C=C1)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Chlorhexidine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N\C(NC1=CC=C(Cl)C=C1)=N/C(N)=N/CCCCCC\N=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1 
     | 
   
  
   
    | InChI Identifier | 
    
       Chlorhexidine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)/f/h31-32H,25-28H2/b29-19+,30-20+,33-21+,34-22+ 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Chlorhexidine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1E)-2-[6-[[amino-[[amino-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[amino-[(4-chlorophenyl)amino]methylidene]guanidine 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  
  |